Go to
JCI Insight
Citations to this article
Pedro Jares, … , Dolors Colomer, Elias Campo
Published October 1, 2012
Citation Information: J Clin Invest. 2012;122(10):3416-3423. https://doi.org/10.1172/JCI61272.
Citation Information: J Clin Invest. 2012;122(10):3416-3423. https://doi.org/10.1172/JCI61272.
Abstract
Mantle cell lymphoma is a B cell malignancy in which constitutive dysregulation of cyclin D1 and the cell cycle, disruption of DNA damage response pathways, and activation of cell survival mechanisms contribute to oncogenesis. A small number of tumors lack cyclin D1 overexpression, suggesting that its dysregulation is always not required for tumor initiation. Some cases have hypermutated IGHV and stable karyotypes, a predominant nonnodal disease, and an indolent clinical evolution, which suggests that they may correspond to distinct subtypes of the disease. In this review, we discuss the molecular pathways that contribute to pathogenesis, and how improved understanding of these molecular mechanisms offers new perspectives for the treatment of patients.
Authors
Pedro Jares, Dolors Colomer, Elias Campo
Total citations by year
Citation information
Citations to this article (155)
| Title and authors | Publication | Year |
|---|---|---|
|
SQSTM1/p62 predicts prognosis and upregulates the transcription of CCND1 to promote proliferation in mantle cell lymphoma.
Zhang S, Huang F, Wang J, You R, Huang Q, Chen Y |
Protoplasma | 2025 |
|
Integrating Single-Cell Biophysical and Transcriptomic Features to Resolve Functional Heterogeneity in Mantle Cell Lymphoma
Zhang Y, Debaize L, Langenbucher A, Weekes J, Vogiatzi I, Miettinen TP, Zhang M, Sumpena E, Liu H, Duquette SM, Hackett L, Zhang J, Baghiyan S, Redd RA, Aryee M, Davids MS, Kim AI, Ryan CE, Weinstock DM, Manalis SR, Murakami MA |
bioRxiv | 2025 |
|
Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma
Hoang NM, Liu Y, Bates PD, Heaton AR, Lopez AF, Liu P, Zhu F, Chen R, Kondapelli A, Zhang X, Selberg PE, Ngo VN, Skala MC, Capitini CM, Rui L |
Cell reports. Medicine | 2024 |
|
Disruption of cyclin D1 degradation leads to the development of mantle cell lymphoma
Lu K, Zhang M, Qin H, Shen S, Song H, Jiang H, Zhang C, Xiao G, Tong L, Jiang Q, Chen D |
Acta pharmaceutica Sinica. B | 2024 |
|
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
Kumar A, Soumerai J, Abramson JS, Barnes JA, Caron P, Chhabra S, Chabowska M, Dogan A, Falchi L, Grieve C, Haydu JE, Johnson PC, Joseph A, Kelly HE, Labarre A, Lue JK, Martignetti R, Mi J, Moskowitz A, Owens C, Plummer S, Puccio M, Salles G, Seshan V, Simkins E, Slupe N, Zhang H, Zelenetz AD |
Blood | 2024 |
|
Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
Till KJ, Abdullah M, Alnassfan T, Janet GZ, Marks T, Coma S, Weaver DT, Pachter JA, Pettitt AR, Slupsky JR |
Scientific Reports | 2023 |
|
A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses.
Araujo-Ayala F, Dobaño-López C, Valero JG, Nadeu F, Gava F, Faria C, Norlund M, Morin R, Bernes-Lasserre P, Serrat N, Playa-Albinyana H, Giménez R, Campo E, Lagarde JM, López-Guillermo A, Gine E, Colomer D, Bezombes C, Pérez-Galán P |
Leukemia | 2023 |
|
CCND1-associated ceRNA network reveal the critical pathway of TPRG1-AS1-hsa-miR-363-3p-MYO1B as a prognostic marker for head and neck squamous cell carcinoma
Li Z, Qiu X, He Q, Fu X, Ji F, Tian X |
Scientific Reports | 2023 |
|
Genomic and Transcriptomic Profiling Reveals Distinct Molecular Subsets Associated with Outcomes in Mantle Cell Lymphoma
Shuhua Yi, Yuting Yan, Meiling Jin, Supriyo Bhattacharya, Yi Wang, Yiming Wu, Lu Yang, Eva Giné, Guillem Clot, Lu Chen, Ying Yu, Dehui Zou, Jun Wang, An T. Phan, Rui Cui, Fei Li, Qi Sun, Qiongli Zhai, Tingyu Wang, Zhen Yu, Lanting Liu, Wei Liu, Rui Lyu, Weiwei Sui, Wenyang huang, Wenjie Xiong, Huijun Wang, Chengwen Li, Zhijian Xiao, Mu Hao, Jianxiang Wang, Tao Cheng, Silvia Bea, Alex F Herrera, Alexey Danilov, Elias Campo, Vu N. Ngo, Lugui Qiu, Lili Wang |
Journal of Clinical Investigation | 2022 |
|
KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders
E Vendramini, R Bomben, F Pozzo, T Bittolo, E Tissino, V Gattei, A Zucchetto |
Cancers | 2022 |
|
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial
E Giné, F de la Cruz, A Ubieto, J Jimenez, A García-Sancho, M Terol, E Barca, M Casanova, A de la Fuente, A Marín-Niebla, A Muntañola, T González-López, M Aymerich, X Setoain, M Cortés-Romera, A Rotger, S Rodríguez, A Herrera, R Sanz, F Nadeu, S Beà, E Campo, A López-Guillermo |
Journal of Clinical Oncology | 2022 |
|
Evaluation of Proteasome Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis
I Chen, Y Liu, Y Wu, S Lo, Z Dai, J Hsu, Y Tseng |
Cells | 2022 |
|
Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma.
Thus YJ, Eldering E, Kater AP, Spaargaren M |
Leukemia | 2022 |
|
Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma
Saleh K, Cheminant M, Chiron D, Burroni B, Ribrag V, Sarkozy C |
Cancers | 2022 |
|
Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database.
Rai S, Tanizawa Y, Cai Z, Huang YJ, Taipale K, Tajimi M |
Advances in Therapy | 2022 |
|
Dihydroorotate dehydrogenase inhibition acts synergistically with tyrosine kinase inhibitors to induce apoptosis of mantle cell lymphoma cells
Eriksen\u2010Gjerstad M, Tveit Karlsen I, Fandalyuk Z, Benjaminsen S, Baran\u2010Marszak F, Papp B, Locke F, Ladds M, Pastor\u2010Fernández A, Gelebart P, Mc Cormack E |
2022 | |
|
CAR T-Cell Therapy in the Older Person: Indications and Risks.
Shouse G, Danilov AV, Artz A |
Current Oncology Reports | 2022 |
|
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies
Alu A, Lei H, Han X, Wei Y, Wei X |
Journal of Hematology & Oncology | 2022 |
|
Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study
Zhang Y, Liu P, Cai J, Jing H, Zou L, Huang H, Wu Y, Li W, Zhong L, Jin X, Ye X, Feng R, Zhang H, Zhang L, Lin L, Sun X, Tian Y, Xia Z, Li Z, Huang H, Xia Y, Cai Q |
Cancer Medicine | 2022 |
|
Tumorigenic role of Musashi-2 in aggressive mantle cell lymphoma
Sureda-Gómez M, Balsas P, Rodríguez ML, Nadeu F, De Bolòs A, Eguileor Á, Kulis M, Castellano G, López C, Giné E, Demajo S, Jares P, Martín-Subero JI, Beà S, Campo E, Amador V |
Leukemia | 2022 |
|
Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation
Thus YJ, de Rooij MF, Swier N, Beijersbergen RL, Guikema JE, Kersten MJ, Eldering E, Pals ST, Kater AP, Spaargaren M |
Haematologica | 2022 |
|
Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma
X Zhao, MY Wang, H Jiang, T Lwin, PM Park, J Gao, MB Meads, Y Ren, T Li, J Sun, NA Fahmi, S Singh, L Sehgal, X Wang, AS Silva, EM Sotomayor, KH Shain, JL Cleveland, M Wang, W Zhang, J Qi, BD Shah, J Tao |
Cell Reports | 2021 |
|
Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia
JS Walker, ZA Hing, S Sher, J Cronin, K Williams, B Harrington, JN Skinner, CB Cempre, CT Gregory, A Pan, M Yano, LP Beaver, BR Walker, JM Labanowska, NA Heerema, K Mrózek, JA Woyach, AS Ruppert, A Lehman, HG Ozer, V Coppola, P Yan, JC Byrd, JS Blachly, R Lapalombella |
Nature Communications | 2021 |
|
P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib
X Zhou, X Li, L Liao, J Han, J Huang, J Li, H Tao, S Fan, Z Chen, Q Li, S Chen, H Ding, Y Yang, B Zhou, H Jiang, K Chen, Y Zhang, C Huang, C Luo |
Acta Pharmacologica Sinica | 2021 |
|
Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma
C Jing, Y Zheng, Y Feng, X Cao, C Xu |
Scientific Reports | 2021 |
|
A Rare Case of Severe Lactic Acidosis in a Patient With Mantle Cell Lymphoma
KH Chan, L Prabhakar, O Al-Radideh, B Okwesili, G Are, H Shaaban |
Journal of Investigative Medicine High Impact Case Reports | 2021 |
|
CDKN1C‐mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib
Y Kagiyama, S Fujita, Y Shima, K Yamagata, T Katsumoto, M Nakagawa, D Honma, N Adachi, K Araki, A Kato, K Inaki, Y Ono, S Fukuhara, Y Kobayashi, K Tobinai, I Kitabayashi |
Cancer Science | 2021 |
|
Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice
T Pieters, S TSas, S Vanhee, A Almeida, Y Driege, J Roels, WV Loocke, W Daneels, M Baens, A Marchand, MV Trimpont, F Matthijssens, J Morscio, K Lemeire, B Lintermans, L Reunes, P Chaltin, F Offner, JV Dorpe, T Hochepied, G Berx, R Beyaert, J Staal, PV Vlierberghe, S Goossens |
Journal of Experimental Medicine | 2021 |
|
Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features
SM Aukema, GA Croci, S Bens, K Oehl-Huber, R Wagener, G Ott, A Rosenwald, PM Kluin, E van den Berg, AG Bosga-Bouwer, M Hoogendoorn, E Hoster, I Bittmann, I Nagel, EM Penas, M Kreuz, J Bausinger, W Belder, I Oschlies, MJ Dyer, S Jayne, R Siebert, W Klapper |
Virchows Archiv | 2021 |
|
Detailed characterization of the transcriptome of single B cells in mantle cell lymphoma suggesting a potential use for SOX4
SV Hansen, MH Hansen, O Cédile, MB Møller, J Haaber, N Abildgaard, CG Nyvold |
Scientific Reports | 2021 |
|
Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
X Wang, Y Fei, X Liu, T Zhang, W Li, X Jia, X Liu, L Qiu, Z Qian, S Zhou, X Ren, Q Zhai, B Meng, L Li, H Zhang |
Aging | 2021 |
|
Progress in molecular feature of smoldering mantle cell lymphoma
P Jiang, A Desai, H Ye |
Experimental Hematology and Oncology | 2021 |
|
Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation
R Vilarrasa-Blasi, P Soler-Vila, N Verdaguer-Dot, N Russiñol, MD Stefano, V Chapaprieta, G Clot, I Farabella, P Cuscó, M Kulis, X Agirre, F Prosper, R Beekman, S Beà, D Colomer, HG Stunnenberg, I Gut, E Campo, MA Marti-Renom, JI Martin-Subero |
Nature Communications | 2021 |
|
[Efficacy and prognostic analysis of frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone regimens (VR-CAP) for patients with mantle cell lymphoma]
Y W Cao, Z Zheng, P P Xu, S Cheng, L Wang, Y Qian, W L Zhao |
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi | 2021 |
|
Non‑coding RNAs (miRNAs and lncRNAs) and their roles in lymphogenesis in all types of lymphomas and lymphoid malignancies (Review)
G Drillis, M Goulielmaki, D Spandidos, S Aggelaki, V Zoumpourlis |
Oncology Letters | 2021 |
|
Truncation of 3' CCND1 by t(11;22) leads to negative SP4 CCND1 immunohistochemistry in blastoid mantle cell lymphoma
Fumiyo Maekawa, Chiyuki Kishimori, Miho Nakagawa, Kayo Takeoka, Katsuhiro Fukutsuka, Masahiko Hayashida, Futoshi Iioka, Masakazu Fujimoto, Kengo Takeuchi, Hirokazu Nakamine, Hitoshi Ohno |
Blood Advances | 2021 |
|
Current Knowledge in Genetics, Molecular Diagnostic Tools, and Treatments for Mantle Cell Lymphomas
S Sethi, Z Epstein-Peterson, A Kumar, C Ho |
Frontiers in Oncology | 2021 |
|
The pathologic diagnosis of mantle cell lymphoma
Shaoying Li, Jie Xu, M James You |
Histology and histopathology | 2021 |
|
Clinical and biological features of mantle cell lymphoma patients with co-expression of CD10 and BCL-6: a retrospective study
W Chen, H Liu, P Wang, G Li |
Translational cancer research | 2021 |
|
A Cyclin D1–Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma
S Demajo, R Albero, G Clot, G Castellano, A Navarro, C Capdevila, A Enjuanes, F Nadeu, E Giné, M Pinyol, ES Jaffe, G Ott, LM Staudt, A Rosenwald, DW Scott, LM Rimsza, A López-Guillermo, S Beà, E Campo, P Jares |
Clinical cancer research | 2020 |
|
Linking Environmental Exposures to Molecular Pathogenesis in Non-Hodgkin Lymphoma Subtypes
L Moubadder, LE McCullough, CR Flowers, JL Koff |
Cancer epidemiology, biomarkers & prevention | 2020 |
|
MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma
L Wang, G Tang, LJ Medeiros, J Xu, W Huang, CC Yin, M Wang, P Jain, P Lin, S Li |
Haematologica | 2020 |
|
An overlapping case of in situ mantle cell neoplasia and leukemic non-nodal mantle cell lymphoma
R Matsuoka, N Sakamoto, M Sakata-Yanagimoto, S Chiba, M Noguchi, N Nakamura |
Journal of Clinical and Experimental Hematopathology | 2020 |
|
Management of Drug Resistance in Mantle Cell Lymphoma
G Roué, B Sola |
Cancers | 2020 |
|
Mouse Models in the Study of Mature B-Cell Malignancies
L Pasqualucci, U Klein |
Cold Spring Harbor Perspectives in Medicine | 2020 |
|
MiR-132-3p serves as a tumor suppressor in mantle cell lymphoma via directly targeting SOX11
B Wu, J Li, H Wang, Q Wu, H Liu |
Naunyn-Schmiedeberg's Archives of Pharmacology | 2020 |
|
Inflammatory Infiltrate and Angiogenesis in Mantle Cell Lymphoma
T Annese, G Ingravallo, R Tamma, MD Giorgis, E Maiorano, T Perrone, F Albano, G Specchia, D Ribatti |
Translational oncology | 2020 |
|
Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes
F Nadeu, D Martin-Garcia, G Clot, A Díaz-Navarro, M Duran-Ferrer, A Navarro, R Vilarrasa-Blasi, M Kulis, R Royo, J Gutiérrez-Abril, R Valdés-Mas, C López, V Chapaprieta, M Puiggros, G Castellano, D Costa, M Aymerich, P Jares, B Espinet, A Muntañola, I Ribera-Cortada, R Siebert, D Colomer, D Torrents, E Gine, A López-Guillermo, R Küppers, JI Martin-Subero, XS Puente, S Beà, E Campo |
Blood | 2020 |
|
Stabilization of β-catenin upon B-cell receptor signaling promotes NF-kB target genes transcription in mantle cell lymphoma
G Lazarian, C Friedrich, A Quinquenel, J Tran, S Ouriemmi, E Dondi, A Martin, I Mihoub, D Chiron, C Bellanger, C Fleury, P Gélébart, E McCormack, D Ledoux, C Thieblemont, J Marzec, JG Gribben, F Cymbalista, N Varin-Blank, L Gardano, F Baran-Marszak |
Oncogene | 2020 |
|
Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas
J Gao, MY Wang, Y Ren, T Lwin, T Li, JC Yan, EM Sotomayor, DR Duckett, BD Shah, KH Shain, X Zhao, J Tao |
Haematologica | 2020 |
|
Molecular Pathogenesis of Mantle Cell Lymphoma
A Navarro, S Beà, P Jares, E Campo |
Hematology/Oncology Clinics of North America | 2020 |
|
Single-cell RNA-seq reveals the immune escape and drug resistance mechanisms of mantle cell lymphoma
L Wang, S Mo, X Li, Y He, J Yang |
Cancer biology & medicine | 2020 |
|
Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date Y Sawalha, DA Bond, L Alinari |
OncoTargets and therapy | 2020 |
|
Inhibition of cyclin-dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma.
Zhao X, Bodo J, Chen R, Durkin L, Souers AJ, Phillips DC, Hsi ED |
2020 | |
|
Therapeutic antibodies for mantle cell lymphoma: A brand-new era ahead
M Sun, H Zhang |
Heliyon | 2019 |
|
Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application
Mulder, Wahlin, Österborg, Palma |
Cancers | 2019 |
|
Prohibitin: A hypothetical target for sex-based new therapeutics for metabolic and immune diseases
S Mishra, BL Nyomba |
Experimental biology and medicine (Maywood, N.J.) | 2019 |
|
A high mutation rate of immunoglobulin heavy chain variable region gene associates with a poor survival and chemotherapy response of mantle cell lymphoma patients:
X Li, N Wu, B Li |
Medicine | 2019 |
|
RIP sequencing in mantle cell lymphoma identifies functional long non-coding RNAs associated with translation machinery
G Hu, Y Zhang, M Gupta |
Blood Cancer Journal | 2019 |
|
Cyclin D1 + large B-cell lymphoma with altered CCND1 and BCL-6 rearrangements: a diagnostic challenge
D Gao, Z Liu |
Biomarker Research | 2019 |
|
Feature article: Development of a clinically relevant chemoresistant mantle cell lymphoma cell culture model
J He, KA Hajj, CM Knapp, KA Whitehead |
Experimental biology and medicine (Maywood, N.J.) | 2019 |
|
Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy
E Silkenstedt, F Arenas, B Colom-Sanmartí, S Xargay-Torrent, M Higashi, A Giró, V Rodriguez, P Fuentes, WE Aulitzky, H van der Kuip, S Beà, ML Toribio, E Campo, M López-Guerra, D Colomer |
Journal of Experimental & Clinical Cancer Research | 2019 |
|
Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma
A Maes, K Maes, P Vlummens, HD Raeve, J Devin, V Szablewski, KD Veirman, E Menu, J Moreaux, K Vanderkerken, ED Bruyne |
Blood Cancer Journal | 2019 |
|
Integrating clinical, molecular, proteomic and histopathological data within the tissue context: tissunomics
SR y Cajal, S Hümmer, V Peg, XM Guiu, ID Torres, J Castellvi, E MartinezSaez, J HernandezLosa |
Histopathology | 2019 |
|
Mantle Cell Lymphoma: Which Patients Should We Transplant?
JN Gerson, SK Barta |
Current Hematologic Malignancy Reports | 2019 |
|
Divergent clonal evolution of a common precursor to mantle cell lymphoma and classic Hodgkin lymphoma
H Tashkandi, K Petrova-Drus, CL Batlevi, ME Arcila, M Roshal, F Sen, J Yao, J Baik, A Bilger, J Singh, S de Frank, A Kumar, R Aryeequaye, Y Zhang, A Dogan, W Xiao |
Molecular Case Studies | 2019 |
|
Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma
MA Dengler, CE Teh, R Thijssen, L Gangoda, P Lan, MJ Herold, DH Gray, GL Kelly, AW Roberts, JM Adams |
Oncogene | 2019 |
|
Molecular profiling and management of mantle cell lymphoma
J Ruan |
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program | 2019 |
|
BRD4-Regulated Molecular Targets in Mantle Cell Lymphoma: Insights into Targeted Therapeutic Approach
T Tsukamoto, S Nakahata, R Sato, A Kanai, M Nakano, Y Chinen, S Maegawa-Matsui, Y Matsumura-Kimoto, T Takimoto-Shimomura, Y Mizuno, S Kuwahara-Ota, Y Kawaji, M Taniwaki, T Inaba, K Tashiro, K Morishita, J Kuroda |
Cancer genomics & proteomics | 2019 |
|
Identification and characterization of the cellular subclones that contribute to the pathogenesis of mantle cell lymphoma
J Tang, L Zhang, T Zhou, Z Sun, L Kong, L Jing, H Xing, H Wu, Y Liu, S Zhou, J Li, M Chen, F Xu, J Tang, T Ma, M Hu, D Liu, J Guo, X Zhu, Y Chen, T Ye, J Wang, X Li, HR Xing |
Genes & Diseases | 2019 |
|
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
JN Gerson, E Handorf, D Villa, AS Gerrie, P Chapani, S Li, LJ Medeiros, MI Wang, JB Cohen, O Calzada, MC Churnetski, BT Hill, Y Sawalha, FJ Hernandez-Ilizaliturri, S Kothari, JM Vose, MA Bast, TS Fenske, SN Gari, KJ Maddocks, D Bond, V Bachanova, B Kolla, J Chavez, B Shah, F Lansigan, TF Burns, AM Donovan, N Wagner-Johnston, M Messmer, A Mehta, JK Anderson, N Reddy, AE Kovach, DJ Landsburg, M Glenn, DJ Inwards, R Karmali, JB Kaplan, PF Caimi, S Rajguru, A Evens, A Klein, E Umyarova, B Pulluri, JE Amengual, JK Lue, C Diefenbach, RI Fisher, SK Barta |
Journal of Clinical Oncology | 2019 |
|
Turning Point in the Treatment of Mantle Cell Lymphoma
Motokura T |
2019 | |
|
Beyond molecular tumor heterogeneity: protein synthesis takes control
SR y Cajal, J Castellvi, S Hümmer, V Peg, J Pelletier, N Sonenberg |
Oncogene | 2018 |
|
The NOTCH Pathway and Its Mutations in Mature B Cell Malignancies
F Arruga, T Vaisitti, S Deaglio |
Frontiers in Oncology | 2018 |
|
ZEB Proteins in Leukemia: Friends, Foes, or Friendly Foes?
B Soen, N Vandamme, G Berx, J Schwaller, PV Vlierberghe, S Goossens |
2018 | |
|
Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA
S Heine, M Kleih, N Giménez, K Böpple, G Ott, D Colomer, WE Aulitzky, H van der Kuip, E Silkenstedt |
Journal of Hematology & Oncology | 2018 |
|
CD40L mediated alternative NFκB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma
H Rauert-Wunderlich, M Rudelius, I Berberich, A Rosenwald |
Cell Death and Disease | 2018 |
|
Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network
H Rauert-Wunderlich, A Mottok, DW Scott, LM Rimsza, G Ott, W Klapper, M Unterhalt, HC Kluin-Nelemans, O Hermine, S Hartmann, C Thorns, G Rymkiewicz, H Holte, M Dreyling, E Hoster, A Rosenwald |
British Journal of Haematology | 2018 |
|
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial
R Bomben, S Ferrero, T DAgaro, MD Bo, A Re, A Evangelista, AM Carella, A Zamò, U Vitolo, P Omedè, C Rusconi, L Arcaini, L Rigacci, S Luminari, A Piccin, D Liu, A Wiestner, G Gaidano, S Cortelazzo, M Ladetto, V Gattei |
Haematologica | 2018 |
|
Molecular signatures for CCN1, p21 and p27 in progressive mantle cell lymphoma
AR Zaidi, S Dresman, C Burt, S Rule, L McCallum |
Journal of Cell Communication and Signaling | 2018 |
|
Noninfectious Cloudy Peritoneal Effluent in a Peritoneal Dialysis Patient with Mantle Cell Lymphoma
D Vigil, MD Reyes, S Polak, Y Sun, L Blacklock, AH Tzamaloukas |
Cureus | 2018 |
|
Nomogram incorporating clinicopathological parameters to predict the survival of patients with mantle cell lymphoma
Y Zhu, W Xu, X Zheng, Z Zheng |
Journal of Investigative Medicine | 2018 |
|
Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP 53 alterations
RJ Lin, C Ho, PD Hilden, JN Barker, SA Giralt, PA Hamlin, AA Jakubowski, HR CastroMalaspina, KS Robinson, EB Papadopoulos, MA Perales, CS Sauter |
British Journal of Haematology | 2018 |
|
CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1 − mantle cell lymphoma
D Martín-Garcia, A Navarro, R Valdés-Mas, G Clot, J Gutiérrez-Abril, M Prieto, I Ribera-Cortada, R Woroniecka, G Rymkiewicz, S Bens, L de Leval, A Rosenwald, JA Ferry, ED Hsi, K Fu, J Delabie, D Weisenburger, D de Jong, F Climent, SJ OConnor, SH Swerdlow, D Torrents, S Beltran, B Espinet, B González-Farré, L Veloza, D Costa, E Matutes, R Siebert, G Ott, L Quintanilla-Martinez, ES Jaffe, C López-Otín, I Salaverria, XS Puente, E Campo, S Beà |
Blood | 2018 |
|
Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
X Zhao, T Lwin, A Silva, B Shah, J Tao, B Fang, L Zhang, K Fu, C Bi, J Li, H Jiang, MB Meads, T Jacobson, M Silva, A Distler, L Darville, L Zhang, Y Han, D Rebatchouk, MD Liberto, LC Moscinski, JM Koomen, WS Dalton, KH Shain, M Wang, E Sotomayor, J Tao |
Nature Communications | 2017 |
|
The role of B cell antigen receptors in mantle cell lymphoma
M Fichtner, M Dreyling, M Binder, M Trepel |
Journal of Hematology & Oncology | 2017 |
|
MicroRNA‑193a‑3p inhibits cell proliferation in prostate cancer by targeting cyclin D1
Y Liu, X Xu, X Xu, S Li, Z Liang, Z Hu, J Wu, Y Zhu, X Jin, X Wang, Y Lin, H Chen, Y Mao, J Luo, X Zheng, L Xie |
Oncology Letters | 2017 |
|
New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies
DW Scott, P Abrisqueta, GW Wright, GW Slack, A Mottok, D Villa, P Jares, H Rauert-Wunderlich, C Royo, G Clot, M Pinyol, M Boyle, FC Chan, RM Braziel, WC Chan, DD Weisenburger, JR Cook, TC Greiner, K Fu, G Ott, J Delabie, EB Smeland, H Holte, ES Jaffe, C Steidl, JM Connors, RD Gascoyne, A Rosenwald, LM Staudt, E Campo, LM Rimsza |
Journal of Clinical Oncology | 2017 |
|
The drive to generate multiple forms of oncogenic cyclin D1 transcripts in mantle cell lymphoma
CP Masamha |
Biomarker Research | 2017 |
|
Current and emerging treatment options for mantle cell lymphoma
B Fakhri, B Kahl |
Therapeutic Advances in Hematology | 2017 |
|
A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress
KB Younes, S Body, É Costé, PJ Viailly, H Miloudi, C Coudre, F Jardin, FB Aissa-Fennira, B Sola |
BMC Cancer | 2017 |
|
CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course
Z Hu, Y Sun, EJ Schlette, G Tang, S Li, J Xu, CC Yin, KH Young, KP Patel, RN Miranda, M Goswami, M Wang, JL Jorgensen, LJ Medeiros, SA Wang |
Modern Pathology | 2017 |
|
Long non-coding RNA profile in mantle cell lymphoma identifies a functional lncRNA ROR1-AS1 associated with EZH2/PRC2 complex
G Hu, SK Gupta, TP Troska, A Nair, M Gupta |
Oncotarget | 2017 |
|
Proteasome-associated deubiquitinases and cancer
A Mofers, P Pellegrini, S Linder, P DArcy |
Cancer and Metastasis Reviews | 2017 |
|
The evolving role of targeted biological agents in the management of indolent B-cell lymphomas
TP Wang, JH Scott, SK Barta |
Therapeutic Advances in Hematology | 2017 |
|
Smoldering mantle cell lymphoma
H Ye, A Desai, D Zeng, K Nomie, J Romaguera, M Ahmed, ML Wang |
Journal of Experimental & Clinical Cancer Research | 2017 |
|
CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases
J Xu, LJ Medeiros, A Saksena, M Wang, J Zhou, J Li, CC Yin, G Tang, L Wang, P Lin, S Li |
Oncotarget | 2017 |
|
Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment
M Rudelius, MT Rosenfeldt, E Leich, H Rauert-Wunderlich, AG Solimando, A Beilhack, G Ott, A Rosenwald |
Haematologica | 2017 |
|
Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas
S Fu, M Wang, DR Lairson, R Li, B Zhao, XL Du |
Oncotarget | 2017 |
|
Efficacy and safety of ibrutinib in indian patients with relapsed or refractory chronic lymphocytic leukemia and mantle cell lymphoma: Cases from a named patient program
MB Agarwal, D Bhurani, C Shah, N Sood, M Singhal, A Kamat, S Chezhian, S Mishra, D Nagrale |
Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology | 2017 |
|
BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells
B Sun, W Fiskus, Y Qian, K Rajapakshe, K Raina, KG Coleman, AP Crew, A Shen, DT Saenz, CP Mill, AJ Nowak, N Jain, L Zhang, M Wang, JD Khoury, C Coarfa, CM Crews, KN Bhalla |
Leukemia | 2017 |
|
Clinical Impact of the 2016 Update to the WHO Lymphoma Classification
RC Lynch, D Gratzinger, RH Advani |
Current Treatment Options in Oncology | 2017 |
|
B-cell lymphomas with discordance between pathological features and clinical behavior
L de Leval, C Copie-Bergman, A Rosenwald, L Rimsza, S Pittaluga, B Bisig, S Dirnhofer, F Facchetti, S Pileri, F Fend, A Wotherspoon |
Virchows Archiv | 2017 |
|
Targeting B-cell receptor signaling in leukemia and lymphoma: how and why?
JC Allen, F Talab, JR Slupsky |
International Journal of Hematologic Oncology | 2016 |
|
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies
C Evangelisti, C Evangelisti, F Buontempo, A Lonetti, E Orsini, F Chiarini, JT Barata, S Pyne, NJ Pyne, AM Martelli |
Leukemia | 2016 |
|
Modulation of p73 isoforms expression induces anti-proliferative and pro-apoptotic activity in mantle cell lymphoma independent of p53 status
HM Hassan, ML Varney, NK Chaturvedi, SS Joshi, DD Weisenburger, RK Singh, BJ Dave |
Leukemia & Lymphoma | 2016 |
|
FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma
Y Li, MN Bouchlaka, J Wolff, KM Grindle, L Lu, S Qian, X Zhong, N Pflum, P Jobin, BS Kahl, JC Eickhoff, SM Wuerzberger-Davis, S Miyamoto, CJ Thomas, DT Yang, CM Capitini, L Rui |
Oncogene | 2016 |
|
Pathogenic role of B-cell receptor signaling and canonical NF- B activation in mantle cell lymphoma
NS Saba, D Liu, SE Herman, C Underbayev, X Tian, D Behrend, MA Weniger, M Skarzynski, J Gyamfi, L Fontan, A Melnick, C Grant, M Roschewski, A Navarro, S Bea, S Pittaluga, K Dunleavy, WH Wilson, A Wiestner |
Blood | 2016 |
|
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
SH Swerdlow, E Campo, SA Pileri, NL Harris, H Stein, R Siebert, R Advani, M Ghielmini, GA Salles, AD Zelenetz, ES Jaffe |
Blood | 2016 |
|
Development of highly aggressive mantle cell lymphoma after sofosbuvir treatment of hepatitis C
RJ Lin, T Moskovits, CS Diefenbach, KB Hymes |
Blood Cancer Journal | 2016 |
|
Leukemic non-nodal mantle cell lymphomas have a distinct phenotype and are associated with deletion of PARP1 and 13q14
M Gallo, V Cacheux, L Vincent, C Bret, A Tempier, C Guittard, A Macé, N Leventoux, V Costes, V Szablewski |
Virchows Archiv | 2016 |
|
Bortezomib for the treatment of mantle cell lymphoma: an update
B Hambley, PF Caimi, BM William |
Therapeutic Advances in Hematology | 2016 |
|
The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?
M Dreyling, S Ferrero |
Haematologica | 2016 |
|
Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage
AC Queirós, R Beekman, R Vilarrasa-Blasi, M Duran-Ferrer, G Clot, A Merkel, E Raineri, N Russiñol, G Castellano, S Beà, A Navarro, M Kulis, N Verdaguer-Dot, P Jares, A Enjuanes, MJ Calasanz, A Bergmann, I Vater, I Salaverría, HJ van de Werken, WH Wilson, A Datta, P Flicek, R Royo, J Martens, E Giné, A Lopez-Guillermo, HG Stunnenberg, W Klapper, C Pott, S Heath, IG Gut, R Siebert, E Campo, JI Martín-Subero |
Cancer Cell | 2016 |
|
The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma
R Arkwright, TM Pham, JA Zonder, QP Dou |
Expert Opinion on Drug Discovery | 2016 |
|
ZGDHu-1 promotes apoptosis of mantle cell lymphoma cells
L Qiu, Z Wang, S Chen, W Hu, Q Huang, Y Zhou |
Oncotarget | 2016 |
|
Phospholipid scramblase 1 as a critical node at the crossroad between autophagy and apoptosis in mantle cell lymphoma
K Mastorci, B Montico, DA Faè, L Sigalotti, M Ponzoni, G Inghirami, R Dolcetti, JD Col |
Oncotarget | 2016 |
|
Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations
C Wu, NF de Miranda, L Chen, AM Wasik, L Mansouri, W Jurczak, K Galazka, M Dlugosz-Danecka, M Machaczka, H Zhang, R Peng, RD Morin, R Rosenquist, B Sander, Q Pan-Hammarström |
Oncotarget | 2016 |
|
Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents
AA Inamdar, A Goy, NM Ayoub, C Attia, L Oton, V Taruvai, M Costales, YT Lin, A Pecora, KS Suh |
Oncotarget | 2016 |
|
PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers
Y Li, N Chitnis, H Nakagawa, Y Kita, S Natsugoe, Y Yang, Z Li, MA Wasik, AJ Klein-Szanto, AK Rustgi, JA Diehl |
Cancer Discovery | 2015 |
|
Ibrutinib: A Review of Its Use in Patients with Mantle Cell Lymphoma or Chronic Lymphocytic Leukaemia
ES Kim, S Dhillon |
Drugs | 2015 |
|
Cell-specific uptake of mantle cell lymphoma-derived exosomes by malignant and non-malignant B-lymphocytes
I Hazan-Halevy, D Rosenblum, S Weinstein, O Bairey, P Raanani, D Peer |
Cancer Letters | 2015 |
|
Novel Agents in Mantle Cell Lymphoma
A Kumar |
Current Oncology Reports | 2015 |
|
Characteristics of human primary mantle cell lymphoma engraftment in NSG mice
S Iyengar, L Ariza-McNaughton, A Clear, D Taussig, R Auer, A Roe, D Lillington, S Iqbal, S Joel, J Gribben, D Bonnet |
British Journal of Haematology | 2015 |
|
Mantle cell lymphoma—a spectrum from indolent to aggressive disease
B Sander, L Quintanilla-Martinez, G Ott, L Xerri, I Kuzu, JK Chan, SH Swerdlow, E Campo |
Virchows Archiv | 2015 |
|
Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells
L Lorkova, M Scigelova, TN Arrey, O Vit, J Pospisilova, E Doktorova, M Klanova, M Alam, P Vockova, B Maswabi, P Klener, J Petrak, YG Shellman |
PloS one | 2015 |
|
Arsenic trioxide rewires mantle cell lymphoma response to bortezomib
LL Zhao, YF Liu, LJ Peng, AM Fei, W Cui, SC Miao, O Hermine, R Gressin, S Khochbin, SJ Chen, J Wang, JQ Mi |
Cancer Medicine | 2015 |
|
Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype
I Ribera-Cortada, D Martinez, V Amador, C Royo, A Navarro, S Beà, E Gine, L Leval, S Serrano, A Wotherspoon, D Colomer, A Martinez, E Campo |
Modern Pathology | 2015 |
|
Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib
B Sun, B Shah, W Fiskus, J Qi, K Rajapakshe, C Coarfa, L Li, SG Devaraj, S Sharma, L Zhang, ML Wang, DT Saenz, S Krieger, JE Bradner, KN Bhalla |
Blood | 2015 |
|
Nuclear localization of translocation partners in differentiating B-cells
IV Sklyar, AM Pichugin, SV Razin, ES Vassetzky, OV Iarovaia |
Doklady Biochemistry and Biophysics | 2015 |
|
SOX11 defines two different subtypes of mantle cell lymphoma through transcriptional regulation of BCL6
J Palomero, MC Vegliante, A Eguileor, ML Rodríguez, P Balsas, D Martínez, E Campo, V Amador |
Leukemia | 2015 |
|
Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies
S Weinstein, IA Toker, R Emmanuel, S Ramishetti, I Hazan-Halevy, D Rosenblum, M Goldsmith, A Abraham, O Benjamini, O Bairey, P Raanani, A Nagler, J Lieberman, D Peer |
Proceedings of the National Academy of Sciences | 2015 |
|
Identification of miR150b as a transformation-related factor in mantle cell lymphoma
F Arakawa, Y Kimura, N Yoshida, H Miyoshi, A Doi, K Yasuda, K Nakajima, J Kiyasu, D Niino, Y Sugita, K Tashiro, S Kuhara, M Seto, K Ohshima |
International journal of oncology | 2015 |
|
Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199
A Montraveta, S Xargay-Torrent, L Rosich, M López-Guerra, J Roldán, V Rodríguez, E Lee-Vergés, M Frías, C Campàs, E Campo, G Roué, D Colomer |
Oncotarget | 2015 |
|
Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma
Sarkar A, Balakrishnan K, Chen J, Patel V, Neelapu SS, McMurray JS, Gandhi V |
Oncotarget | 2015 |
|
Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma
Chiron D, Dousset C, Brosseau C, Touzeau C, Maïga S, Moreau P, Pellat-Deceunynck C, Le Gouill S, Amiot M |
Oncotarget | 2015 |
|
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia
T Placke, K Faber, A Nonami, SL Putwain, HR Salih, FH Heidel, A Krämer, DE Root, DA Barbie, AV Krivtsov, SA Armstrong, WC Hahn, BJ Huntly, SM Sykes, MD Milsom, C Scholl, S Fröhling |
Blood | 2014 |
|
Targeting Bruton's tyrosine kinase in B cell malignancies
RW Hendriks, S Yuvaraj, LP Kil |
Nature Reviews Cancer | 2014 |
|
The tumour microenvironment in B cell lymphomas
DW Scott, RD Gascoyne |
Nature Reviews Cancer | 2014 |
|
Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma
A Moros, V Rodríguez, I Saborit-Villarroya, A Montraveta, P Balsas, P Sandy, A Martínez, A Wiestner, E Normant, E Campo, P Pérez-Galán, D Colomer, G Roué |
Leukemia | 2014 |
|
Do mantle cell lymphomas have an ‘Achilles heel’?:
N Saba, A Wiestner |
Current Opinion in Hematology | 2014 |
|
Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma
MA Dengler, A Weilbacher, M Gutekunst, AM Staiger, MC Vöhringer, H Horn, G Ott, WE Aulitzky, H der Kuip |
Cell Death and Disease | 2014 |
|
Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents
M Klanova, L Lorkova, O Vit, B Maswabi, J Molinsky, J Pospisilova, P Vockova, C Mavis, L Lateckova, V Kulvait, D Vejmelkova, R Jaksa, F Hernandez, M Trneny, M Vokurka, J Petrak, P Klener |
Molecular Cancer | 2014 |
|
Bortezomib for the treatment of non-Hodgkin’s lymphoma
P Bose, MS Batalo, B Holkova, S Grant |
Expert Opinion on Pharmacotherapy | 2014 |
|
Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma: Cytokines and MCL
MB Sonbol, MJ Maurer, MJ Stenson, C Allmer, BR LaPlant, GJ Weiner, WR Macon, JR Cerhan, TE Witzig, M Gupta |
American Journal of Hematology | 2014 |
|
A Rare Presentation of In Situ Mantle Cell Lymphoma and Follicular Lymphoma: A Case Report and Review of the Literature
J Taverna, A Nair, S Yun, S Paulson, JH Schatz, D Persky, D Fuchs, S Puvvada |
Case Reports in Hematology | 2014 |
|
Mantle cell lymphoma harboring Burkitt’s-like translocations presents differential expression of aurora kinase genes compared with others 8q abnormalities
FM de Oliveira, AP Rodrigues-Alves, AR Lucena-Araújo, F de Paula Silva, FB da Silva, RP Falcão |
Medical Oncology | 2014 |
|
Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma.
Montraveta A, Xargay-Torrent S, López-Guerra M, Rosich L, Pérez-Galán P, Salaverria I, Beà S, Kalko SG, de Frias M, Campàs C, Roué G, Colomer D |
Oncotarget | 2014 |
|
Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma
Rosich L, Montraveta A, Xargay-Torrent S, López-Guerra M, Roldán J, Aymerich M, Salaverria I, Beà S, Campo E, Pérez-Galán P, Roué G, Colomer D |
Oncotarget | 2014 |
|
Microenviromment-Mediated c-Myc-miR-548m-HDAC6 Amplification Loop in Non-Hodgkin B-Cell Lymphomas
Tint Lwin, Xiaohong Zhao, Fengdong Cheng, Xinwei Zhang, Andy huang, Bijal Shah, Yizhuo Zhang, MOSCINSKI Lynn, Yong Sung Choi, Alan Kozikowski, James Bradner, William Dalton, Eduardo Sotomayor, Jianguo Tao |
Journal of Clinical Investigation | 2013 |
|
The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma
E Sánchez-Tilló, L Fanlo, L Siles, S Montes-Moreno, A Moros, G Chiva-Blanch, R Estruch, A Martinez, D Colomer, B Győrffy, G Roué, A Postigo |
Cell Death and Differentiation | 2013 |
|
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma
S Bea, R Valdes-Mas, A Navarro, I Salaverria, D Martin-Garcia, P Jares, E Gine, M Pinyol, C Royo, F Nadeu, L Conde, M Juan, G Clot, P Vizan, LD Croce, DA Puente, M Lopez-Guerra, A Moros, G Roue, M Aymerich, N Villamor, L Colomo, A Martinez, A Valera, JI Martin-Subero, V Amador, L Hernandez, M Rozman, A Enjuanes, P Forcada, A Muntanola, EM Hartmann, MJ Calasanz, A Rosenwald, G Ott, JM Hernandez-Rivas, W Klapper, R Siebert, A Wiestner, WH Wilson, D Colomer, A Lopez-Guillermo, C Lopez-Otin, XS Puente, E Campo |
Proceedings of the National Academy of Sciences | 2013 |
|
Anti-CCR7 therapy exerts a potent anti-tumor activity in a xenograft model of human mantle cell lymphoma
B Somovilla-Crespo, M Alfonso-Pérez, C Cuesta-Mateos, CC Dios, AE Beltrán, F Terrón, JJ Pérez-Villar, C Gamallo-Amat, G Pérez-Chacón, E Fernández-Ruiz, JM Zapata, C Muñoz-Calleja |
Journal of Hematology & Oncology | 2013 |
|
Lymphoid malignancies: many tumor types, many altered genes, many therapeutic challenges
Riccardo Dalla-Favera |
Journal of Clinical Investigation | 2012 |
|
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)